Douglas Jermasek

Insider Reports History

Reporting-owner location: Los Altos, CA
Latest reporting-owner signature: /s/ Doug Jermasek
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Douglas Jermasek

Form 4 holding EVP, Corporate Strategy

Unicycive Therapeutics, Inc.

Security class: Stock Options
Shares / value: 215,500
Estimated value
Report date: 28 Jul 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding EVP, Corporate Strategy

Unicycive Therapeutics, Inc.

Security class: Restricted Stock Units
Shares / value: 169,500
Estimated value
Report date: 14 May 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Douglas Jermasek

4/A UNCY

Unicycive Therapeutics, Inc.

Report period: 14 May 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 Jun 2026, 17:23
Role: EVP, Corporate Strategy
Next action: Open filing details

4 UNCY

Unicycive Therapeutics, Inc.

Report period: 28 Jul 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 30 Jul 2025, 16:30
Role: EVP of Corporate Strategy
Next action: Open filing details

4 UNCY

Unicycive Therapeutics, Inc.

Report period: 12 Aug 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 14 Aug 2024, 16:15
Role: EVP of Corporate Strategy
Next action: Open filing details

4 UNCY

Unicycive Therapeutics, Inc.

Report period: 15 Apr 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Apr 2024, 16:32
Role: EVP of Corporate Strategy
Next action: Open filing details

4 UNCY

Unicycive Therapeutics, Inc.

Report period: 28 Aug 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 30 Aug 2023, 16:45
Role: EVP of Corporate Strategy
Next action: Open filing details

4 UNCY

Unicycive Therapeutics, Inc.

Report period: 11 Jul 2023
Transactions: 5
Transaction value: -$50,000
Accepted by SEC: 13 Jul 2023, 19:33
Role: EVP of Corporate Strategy
Next action: Open filing details

4 UNCY

Unicycive Therapeutics, Inc.

Report period: 08 Mar 2023
Transactions: 1
Transaction value: +$50,000
Accepted by SEC: 09 Mar 2023, 20:32
Role: EVP of Corporate Strategy
Next action: Open filing details

4 UNCY

Unicycive Therapeutics, Inc.

Report period: 21 Nov 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 23 Nov 2022, 07:00
Role: EVP of Corporate Strategy
Next action: Open filing details

3 UNCY

Unicycive Therapeutics, Inc.

Report period: 18 Nov 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 21 Nov 2022, 07:51
Role: EVP of Corporate Strategy
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .